Merck & Co., Inc. (MRK) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
MRK Revenue Growth
Revenue Breakdown (FY 2025)
MRK's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
MRK Revenue Analysis (2014–2025)
As of May 6, 2026, Merck & Co., Inc. (MRK) generated trailing twelve-month (TTM) revenue of $64.93 billion, reflecting modest growth of +4.5% year-over-year. The most recent quarter (Q4 2025) recorded $16.32 billion in revenue, down 5.0% sequentially.
Looking at the longer-term picture, MRK's 5-year compound annual growth rate (CAGR) stands at +9.4%, indicating steady revenue expansion. The company achieved its highest annual revenue of $64.93 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows MRK's business is primarily driven by Pharmaceutical segment (89%), Animal Health segment (10%), and Other Segments (1%). With over half of revenue concentrated in Pharmaceutical segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including PFE (+1.4% YoY), LLY (+47.4% YoY), and ABBV (+8.6% YoY), MRK has underperformed the peer group in terms of revenue growth. Compare MRK vs PFE →
MRK Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MRKCurrent | $64.9B | +4.5% | +9.4% | 36.2% | |
 PFE | $62.6B | +1.4% | +8.5% | 24.7% | |
 LLY | $65.2B | +47.4% | +21.6% | 45.6% | |
 ABBV | $61.2B | +8.6% | +6.0% | 32.8% | |
 BMY | $48.2B | +1.8% | +2.5% | 26.3% | |
 AMGN | $36.7B | +9.1% | +7.6% | 29.1% |
MRK Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $64.93B | +1.2% | $46.73B | 72.0% | $23.49B | 36.2% |
| 2024 | $64.17B | +6.7% | $48.98B | 76.3% | $20.22B | 31.5% |
| 2023 | $60.12B | +1.4% | $43.99B | 73.2% | $2.95B | 4.9% |
| 2022 | $59.28B | +21.7% | $41.87B | 70.6% | $18.28B | 30.8% |
| 2021 | $48.70B | +17.3% | $35.08B | 72.0% | $13.20B | 27.1% |
| 2020 | $41.52B | +6.1% | $27.90B | 67.2% | $5.55B | 13.4% |
| 2019 | $39.12B | -7.5% | $27.11B | 69.3% | $7.93B | 20.3% |
| 2018 | $42.29B | +5.4% | $28.79B | 68.1% | $8.93B | 21.1% |
| 2017 | $40.12B | +0.8% | $27.21B | 67.8% | $6.80B | 16.9% |
| 2016 | $39.81B | +0.8% | $25.78B | 64.8% | $5.50B | 13.8% |
Full MRK Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Should I Buy MRK Right Now?
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
See MRK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MRK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MRK vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMRK — Frequently Asked Questions
Quick answers to the most common questions about buying MRK stock.
Is MRK's revenue growth accelerating or slowing?
MRK revenue growth slowed to +4.5%, below the 5-year CAGR of +9.4%. TTM revenue is $64.9B. The deceleration marks a shift from historical growth rates.
What is MRK's long-term revenue growth rate?
Merck & Co., Inc.'s 5-year revenue CAGR of +9.4% reflects the variable expansion pattern. Current YoY growth of +4.5% is near this long-term average.
How is MRK's revenue distributed by segment?
MRK reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.